Neuroleptic malignant syndrome

Neurology

Illness script · Neurology

Neuroleptic malignant syndrome

Life-threatening hyperdopaminergic blockade reaction to antipsychotics causing hyperthermia, rigidity, autonomic instability, and altered mental status.

This illness script for Neuroleptic malignant syndrome covers predisposing factors, classic presentation, mechanism, workup, management, and the clinical pivots that separate it from look-alikes—written for USMLE Step 1 and clerkship reasoning.

Updated Jul 19, 2026All scripts

01

Predisposing factors

  • Typical antipsychotics (haloperidol) > atypicals; any dopamine antagonist (metoclopramide, promethazine)
  • Abrupt withdrawal of dopaminergic agents (levodopa, amantadine) in Parkinson's patients
  • Rapid dose escalation or high-potency agent initiation
  • Dehydration, agitation, and high ambient temperature increase risk
  • Young males slightly overrepresented; no strong genetic predisposition identified

02

Presentation

  • Classic tetrad: hyperthermia (>38°C), lead-pipe rigidity, altered mental status, autonomic instability
  • Onset hours to days after starting or increasing offending agent; full syndrome in 24–72 h
  • AMS precedes or accompanies rigidity — ranges from confusion to coma
  • Autonomic findings: diaphoresis, tachycardia, labile BP, tachypnea
  • 'Lead-pipe' rigidity (uniform resistance throughout ROM) is pathognomonic quality
  • Fever is HIGH, often >40°C; distinguishes from many other drug reactions

03

Pathophysiology

  • Central D2 receptor blockade in hypothalamus → loss of thermoregulation → hyperthermia
  • D2 blockade in basal ganglia → profound 'lead-pipe' muscular rigidity
  • Rigidity + hyperthermia → rhabdomyolysis → elevated CK, renal failure
  • Autonomic instability from disrupted hypothalamic and peripheral dopamine signaling

04

Diagnostics

  • No single confirmatory test — clinical diagnosis based on tetrad after drug exposure
  • CK markedly elevated (often >1000 U/L); reflects rhabdomyolysis severity
  • CBC: leukocytosis (10,000–40,000); LFTs, BMP for complications
  • Urine myoglobin, creatinine to assess renal injury
  • LP and head CT to exclude infectious/structural causes if diagnosis uncertain

05

Management

  • STOP offending antipsychotic immediately — first and most critical step
  • Aggressive IV fluid resuscitation for rhabdomyolysis and fever; cooling measures
  • Dantrolene (muscle relaxant) for severe rigidity/hyperthermia — reduces mortality
  • Bromocriptine or amantadine (dopamine agonists) to reverse central D2 blockade
  • Benzodiazepines for agitation/rigidity adjunct; ICU admission mandatory
  • Avoid restarting antipsychotics for ≥2 weeks; consider switch to low-potency atypical if essential

06

Clinical pivots

How to separate this script from the look-alikes that show up on exams and on the wards.

  • Serotonin syndrome

    Hyperreflexia + clonus (not lead-pipe rigidity) and onset within hours; cause is serotonergic agents, not antipsychotics

  • Malignant hyperthermia

    Triggered by inhaled anesthetics/succinylcholine in OR, not antipsychotics; ryanodine receptor mutation

  • Anticholinergic toxicity

    Dry skin/mucous membranes and urinary retention; rigidity absent; CK normal

  • Meningitis/encephalitis

    Rigidity is nuchal (meningeal), not lead-pipe generalized; LP is diagnostic; no antipsychotic exposure required

View full library

Educational use only. This illness script is a study framework, not medical advice. Confirm decisions with current guidelines and your clinical supervisors.